11058616

Source:http://linkedlifedata.com/resource/pubmed/id/11058616

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0010181, umls-concept:C0087111, umls-concept:C0205179, umls-concept:C0376358, umls-concept:C1515985
pubmed:issue	21
pubmed:dateCreated	2000-11-24
pubmed:abstractText	The costs and side effects of several antiandrogen therapies for advanced prostate cancer differ substantially. We estimated the cost-effectiveness of antiandrogen therapies for advanced prostate cancer.
pubmed:commentsCorrections	http://linkedlifedata.com/resource/pubmed/commentcorrection/11058616-11058606
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/7503089
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Androgen Antagonists, http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Hormonal, http://linkedlifedata.com/resource/pubmed/chemical/Diethylstilbestrol, http://linkedlifedata.com/resource/pubmed/chemical/Gonadotropin-Releasing Hormone, http://linkedlifedata.com/resource/pubmed/chemical/Prostate-Specific Antigen
pubmed:status	MEDLINE
pubmed:month	Nov
pubmed:issn	0027-8874
pubmed:author	pubmed-author:BayoumiA MAM, pubmed-author:BrownA DAD, pubmed-author:GarberA MAM
pubmed:issnType	Print
pubmed:day	1
pubmed:volume	92
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	1731-9
pubmed:dateRevised	2006-11-15
pubmed:meshHeading	pubmed-meshheading:11058616-Aged, pubmed-meshheading:11058616-Androgen Antagonists, pubmed-meshheading:11058616-Antineoplastic Agents, Hormonal, pubmed-meshheading:11058616-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:11058616-Cost-Benefit Analysis, pubmed-meshheading:11058616-Diethylstilbestrol, pubmed-meshheading:11058616-Disease Progression, pubmed-meshheading:11058616-Gonadotropin-Releasing Hormone, pubmed-meshheading:11058616-Humans, pubmed-meshheading:11058616-Male, pubmed-meshheading:11058616-Markov Chains, pubmed-meshheading:11058616-Neoplasm Recurrence, Local, pubmed-meshheading:11058616-Orchiectomy, pubmed-meshheading:11058616-Prostate-Specific Antigen, pubmed-meshheading:11058616-Prostatic Neoplasms, pubmed-meshheading:11058616-Quality of Life, pubmed-meshheading:11058616-Quality-Adjusted Life Years, pubmed-meshheading:11058616-Survival Analysis, pubmed-meshheading:11058616-Time Factors, pubmed-meshheading:11058616-Treatment Outcome, pubmed-meshheading:11058616-United States
pubmed:year	2000
pubmed:articleTitle	Cost-effectiveness of androgen suppression therapies in advanced prostate cancer.
pubmed:affiliation	Department of Medicine, University of Toronto, and Inner City Health Research Unit, St. Michael's Hospital, Toronto, Canada. ahmed.bayoumi@utoronto.ca
pubmed:publicationType	Journal Article, Research Support, Non-U.S. Gov't